Romanian Registry for Interstitial Lung Diseases (REGIS): inclusion of patients in 3 years

I. Strambu (Bucuresti 5, Romania)

Source: International Congress 2017 – ILDs: clinical problems
Session: ILDs: clinical problems
Session type: Thematic Poster
Number: 868
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Strambu (Bucuresti 5, Romania). Romanian Registry for Interstitial Lung Diseases (REGIS): inclusion of patients in 3 years. 868

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Multicenter Registry of Interstitial Lung Diseases in Brazil
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019

Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020


DANILDA – The First Danish National Interstitial Lung Disease Registry
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019

Increase in hospital admissions in smokers with Interstitial Lung Abnormalities in the Danish Lung Cancer Screening Trial (DLCST)
Source: International Congress 2018 – COPD and chronic respiratory disease: from misclassification to radiological findings
Year: 2018



Clinical picture analysis of idiopathic pulmonary fibrosis (IPF) and lung cancer (LC) concomitance in the population of patients hospitalized in Ist Clinic of Lung Diseases Institute for Tuberculosis and Lung Diseases in Warsaw, Poland in the years 1994-2009
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011


The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic.
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


Cardiac sarcoidosis is more frequent in males – Large cohort (n=1375) sarcoid patients analysis – 5 years experience in the National TB & Lung Diseases Research Institute in Warsaw, Poland
Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases
Year: 2013

Gender perspective in Interstitial Lung Diseases (ILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019

Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used
Source: International Congress 2017 – Rare diseases
Year: 2017

ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly
Source: ERJ Open Res, 6 (4) 00143-2020; 10.1183/23120541.00143-2020
Year: 2020



Collaboration between the Russian National CF Patient Registry and the European CF Society Patient Registry
Source: International Congress 2018 – Russian Speaking Programme 2018: Part I
Year: 2018


ISHLT Registry Data and Country Registries: Comparison of reported European Lung Transplant Activities in 2016
Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes
Year: 2019


Comorbidities in 1779 sarcoidosis patients – 4 years experience in National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland
Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach
Year: 2012

Hospitalisation pattern in Interstitial Lung Diseases: a claims data study
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018


The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration
Source: Eur Respir J, 52 (6) 1801855; 10.1183/13993003.01855-2018
Year: 2018



Contamination during 4-5 years of annual CT screening in the Danish Lung Cancer Screening Trial (DLCST)
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010


2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Source: Eur Respir J 2015; 46: 903-975
Year: 2015



Case Series of COVID-19 Disease in Pediatric Chronic Lung Diseases
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021


Consequences of Lung Cancer: Mortality and Comorbidity in Danish Patients with Lung Cancer 1998-2010
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019


Lung Cancer Screening Programs: a missed “window” to diagnose Obstructive Lung Disease. The NLST-ACRIN experience.
Source: International Congress 2018 – Interdependence of COPD and comorbidities and the underlying mechanisms
Year: 2018